ADI-PEG 20 (oncology)

Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase

MP Kelly, AA Jungbluth, B-W Wu, J Bomalaski, LJ Old and G Ritter
British Journal of Cancer (2012), Vol. 106 pages 324-332

Activation of Ras/PI3K/ERK Pathway Induces c-Myc Stabilization to Upregulate Argininosuccinate Synthetase, Leading to Arginine Deiminase Resistance in Melanoma Cells

Wen-Bin Tsai, Isamu Aiba, Yan Long, Hui-Kuan Lin, Lynn Feun, Niramol Savaraj, and Macus Tien Kuo
Cancer Research(2012), Vol. 72 pages 2622-2633

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase

LG Feun, A Marini, G Walker, G Elgart, F Moffat, SE Rodgers, CJWu, M You, M Wangpaichitr, MT Kuo, W Sisson, AA Jungbluth, J Bomalaski and N Savaraj
British Journal of Cancer (2012), Vol. 106 pages 1481-1485

Reduced Argininosuccinate Synthetase Is a Predictive Biomarker for the Development of Pulmonary Metastasis in Patients with Osteosarcoma

E. Kobayashi, M. Masuda, R. Nakayama, H. Ichikawa, R. Satow, M. Shitashige, K. Honda, U. Yamaguchi, A. Shoji, N. Tochigi, H. Morioka, Y. Toyama, S. Hirohashi, A. Kawai, T. Yamada
Molecular Cancer Therapeutics (2010), Vol. 9 pages 535-44

Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer

B. Delage, D.A. Fennell, L. Nicholson, I. McNeish, N.R. Lemoine, T. Crook, P.W. Szlosarek
International Journal of Cancer (2010), Vol. 126 pages 2762-2772

Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes

M.T. Kuo, N. Savaraj, L.G. Feun
Oncotarget (2010), Vol. 1 pages 246-251

Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma

E.S. Glazer, M. Piccirillo, V. Albino, R.D. Giacomo, R. Palaia, A.A. Mastro, G. Beneduce, G. Castello, V.D. Rosa, A. Petrillo, P.A. Ascierto, S.A. Curley, F. Izzo
Journal of Clinical Oncology (2010), Vol. 28 pages 2220-2226

A randomised phase II study of pegylated arginine deiminase(ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients

T-S Yang, S-N Lu, Y Chao, I-S Sheen, C-C Lin, T-E Wang, S-C Chen, J-H Wang, L-Y Liao, JA Thomson, J Wang-Peng, P-J Chenand L-T Chen
British Journal of Cancer (2010), Vol. 103 pages 954-960

Arginine Deprivation, Autophagy, Apoptosis (AAA) for the Treatment of Melanoma

N. Savaraj, M. You, C. Wu, M. Wangpaichitr, M.T. Kuo and L.G. Feun
Current Molecular Medicine(2010), Vol. 10 pages 405-412

Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis

R.H. Kim, J.M. Coates, T.L. Bowles, G.P. McNerney, J. Sutcliffe, J.U. Jung, R. Gandour-Edwards, F.Y. Chuang, R.J. Bold, and H.J. Kung
Cancer Research (2009), Vol. 69 pages 700-708

ADI, autophagy, and apoptosis: metabolic stress as a therapeutic option for prostate cancer

R.H. Kim, R.J. Bold, H.J. Kung
Autophagy (2009), Vol. 5 pages 567-568

Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1α/Sp4

W-B Tsai, I. Aiba, S-y Lee, L. Feun, N. Savaraj, M.T. Kuo
Molecular Cancer Therapy(2009), Vol. 8 pages 3223-33

Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer

L.J. Nicholson, P.R. Smith, L. Hiller, P.W. Szlosarek, C. Kimberley, J. Sehouli, D. Koensgen, A. Mustea, P. Schmid, T. Crook
International Journal of Cancer (2009), Vol. 125 pages 1454-1463

Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase

T.L. Bowles, R. Kim, J. Galante, C.M. Parsons, S. Virudachalam, H-J. Kung and R.J. Bold
International Journal of Cancer (2008), Vol. 123 pages 1950-1955

Arginine deprivation as a targeted therapy for cancer

L. Feun, M. You, C.J. Wu, M.T. Kuo, M. Wangpaichitr, S. Spector and N. Savaraj
Current Pharmaceutical Design (2008), Vol. 14 pages 1049-1057

Aberrant regulation of argininosuccinate synthetase by TNF-α in human epithelial ovarian cancer

P.W. Szlosarek, M.J. Grimshaw, G.D. Wilbanks, T. Hagemann, J.L. Wilson, F. Burke, G. Stamp and F.R. Balkwill
International Journal of Cancer (2007), Vol. 121 pages 6-11

The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma

N. Savaraj, C. Wu, M.T. Kuo, M. You, M. Wangpaichitr, C. Robles, S. Spector and L. Feun
Drug Target Insights (2007), Vol. 2 pages 119-128

Pegylated arginine deiminase: a novel anticancer enzyme agent

L. Feun and N. Savaraj
Expert Opinions on Investigational Drugs (2006), Vol. 15 pages 815-822

In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion

P.W. Szlosarek, A. Klabatsa, A. Pallaska, M. Sheaff, P. Smith, T. Crook, M.J. Grimshaw, J.P. Steele, R.M. Rudd, F.R. Balkwill and D.A. Fennell
Clinical Cancer Research (2006), Vol. 12 pages 7126-7135

Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies

P.A. Ascierto, S. Scala, G. Castello, A. Daponte, E. Simeone, A. Ottaiano, G. Beneduce, V. De Rosa, F. Izzo, M.T. Melucci, C.M. Ensor, A.W. Prestayko, F.W. Holtsberg, J.S. Bomalaski, M.A. Clark, N. Savaraj, L.G. Feun and T.F. Logan
Journal of Clinical Oncology (2005), Vol. 23 pages 7660-7668

Incidence and distribution of argininosuccinate synthetase deficiency in human cancers

B.J. Dillon, V.G. Prieto, S.A. Curley, C.M. Ensor, F.W. Holtsberg, J.S. Bomalaski and M.A. Clark
Cancer (2004), Vol. 100 pages 826-833

Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies

F. Izzo, P. Marra, G. Beneduce, G. Castello, P. Vallone, V. De Rosa, F. Cremona, C.M. Ensor, F.W. Holtsberg, J.S. Bomalaski, M.A. Clark, C. Ng and S.A. Curley
Journal of Clinical Oncology (2004), Vol. 22 pages 1815-182

Comparative toxicity of arginine deiminase formulated with poly(ethylene glycol) 5000 or 20,000 and the effects of arginine

J.S. Bomalaski, J.L. Ivett, M. Vegarra, F.W. Holtsberg, C.M. Ensor and M.A. Clark
Preclinica (2003), Vol. 1 pages 284-293

Regression of hepatocellular cancer in a patient treated with arginine deiminase

S.A Curley, J.S. Bomalaski, C.M.Ensor, F.W. Holtsberg and M.A. Clark
Hepatogastroenterology (2003), Vol. 50 pages 1214-1216

Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties

F.W. Holtsberg, C.M. Ensor, M.R. Steiner, J.S. Bomalaski and M.A. Clark
Journal of Controlled Release (2002), Vol. 23 pages 259-271

Enzymic degradation of plasma arginine using arginine deiminase inhibits nitric oxide production and protects mice from the lethal effects of tumour necrosis factor α and endotoxin

J.B. Thomas, F.W. Holtsberg, C.M. Ensor, J.S. Bomalaski and M.A. Clark
Biochemical Journal (2002), Vol. 363 pages 581-587

Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production

B. Dillon, F. Holtsberg, C. Ensor, J. Bomalaski and M. Clark
Medical Science Monitor (2002), Vol. 8 pages BR248-253

Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo

C.M. Ensor, F.W. Holtsberg, J.S. Bomalaski and M.A. Clark
Cancer Research (2002), Vol. 62 pages 5443-5450

Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo

C.M. Ensor, F.W. Holtsberg, J.S. Bomalaski and M.A. Clark
Cancer Research (2002), Vol. 62 pages 5443-5450